AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00435-07v1
51/12/4521    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clouse, F. L.
Right arrow Articles by Rotschafer, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clouse, F. L.
Right arrow Articles by Rotschafer, J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4521-4524, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00435-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Evaluation of the Activities of Telavancin, Cefazolin, and Vancomycin against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus in Peritoneal Dialysate{triangledown}

Frances L. Clouse, Laurie B. Hovde, and John C. Rotschafer*

The University of Minnesota College of Pharmacy, Antibiotic Pharmacodynamic Research Institute, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota

Received 29 March 2007/ Returned for modification 11 May 2007/ Accepted 22 September 2007

This study compared the ability of telavancin to the ability of cefazolin and vancomycin to eliminate staphylococci from peritoneal dialysis fluid by using a static in vitro model to simulate the conditions of peritoneal dialysis. The results showed that telavancin exhibited statistically significantly better kill (P < 0.05) against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

* Corresponding author. Mailing address: University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, 9-157 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN 55455. Phone: (612) 624-2183. Fax: (612) 626-5082. E-mail: rotsc001{at}umn.edu

{triangledown} Published ahead of print on 1 October 2007.

Antimicrobial Agents and Chemotherapy, December 2007, p. 4521-4524, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00435-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.